Monitoring and Management of Patients on Therapy for Chronic Hepatitis B

You answered:

C As soon as the patient obtains an undetectable HBV DNA level, it is advisable for him to stop therapy.

This answer is incorrect. If a patient stops therapy at the first instance of an undetectable HBV DNA, it is quite likely that the HBV DNA will rebound, possibly causing a flare of hepatitis. For HBeAg-positive patients, antiviral therapy should be continued for at least 6 months after the HBV DNA is undetectable and HBeAg seroconversion has occurred.

Choose another answer:

A For HBeAg-positive patients, monitoring for HBeAg seroconversion should occur only after the patient has achieved HBsAg seroconversion.
B After starting therapy, the patient should have his ALT and HBV DNA level next measured at the end of 1 year of therapy.
D If the patient’s HBV DNA level declines by 1 log10 after 6 months of therapy, the response is termed a primary non-response.

[Back to Question | Go to Correct Answer]